PuSH - Publikationsserver des Helmholtz Zentrums München

Napieralski, R.* ; Schricker, G.* ; Auer, G.* ; Aubele, M.* ; Perkins, J.* ; Magdolen, V.* ; Ulm, K.* ; Hamann, M.* ; Walch, A.K. ; Weichert, W.* ; Kiehle, M.* ; Weichert, O.G.*

PITX2 DNA-methylation: Predictive versus prognostic value for anthracycline-based chemotherapy in triple-negative breast cancer patients.

Breast Care 16, 523-531 (2021)
Verlagsversion DOI PMC
Free by publisher
Background: PITX2 DNA methylation has been shown to predict outcomes in high-risk breast cancer patients after anthracycline-based chemotherapy. To determine its prognostic versus predictive value, the impact of PITX2 DNA methylation on outcomes was studied in an untreated cohort vs. an anthracycline-treated triple-negative breast cancer (TNBC) cohort. Material and Methods: The percent DNA methylation ratio (PMR) of paired-like homeodomain transcription factor 2 (PITX2) was determined by a validated methylation-specific real-time PCR test. Patient samples of routinely collected archived formalin-fixed paraffin-embedded (FFPE) tissue and clinical data from 144 TNBC patients of 2 independent cohorts (i.e., 66 untreated patients and 78 patients treated with anthracycline-based chemotherapy) were analyzed. Results: The risk of 5- and 10-year overall survival (OS) increased continuously with rising PITX2 DNA methylation in the anthracycline-treated population, but it increased only slightly during 10-year follow-up time in the untreated patient population. PITX2 DNA methylation with a PMR cutoff of 2 did not show significance for poor vs. good outcomes (OS) in the untreated patient cohort (HR = 1.55; p = 0.259). In contrast, the PITX2 PMR cutoff of 2 identified patients with poor (PMR >2) vs. good (PMR ≤2) outcomes (OS) with statistical significance in the anthracycline-treated cohort (HR = 3.96; p = 0.011). The results in the subgroup of patients who did receive anthracyclines only (no taxanes) confirmed this finding (HR = 5.71; p = 0.014). Conclusion: In this hypothesis-generating study PITX2 DNA methylation demonstrated predominantly predictive value in anthracycline treatment in TNBC patients. The risk of poor outcome (OS) correlates with increasing PITX2 DNA methylation.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Anthracyclines ; Biomarker ; Chemotherapy ; Dna Methylation ; Homeodomain Proteins/genetics ; Pitx2 ; Therapy Prediction ; Treatment Outcome ; Triple-negative Breast Cancer/neoplasms ; Tumor/genetics; Adjuvant Chemotherapy; Clinical Validation; Cell; Multicenter; Activation; Biomarker; Pathway; Marker; Risk
ISSN (print) / ISBN 1661-3791
e-ISSN 1661-3805
Zeitschrift Breast Care
Quellenangaben Band: 16, Heft: 5, Seiten: 523-531 Artikelnummer: , Supplement: ,
Verlag Karger
Verlagsort Allschwilerstrasse 10, Ch-4009 Basel, Switzerland
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Research Unit Analytical Pathology (AAP)
Förderungen Therawis Diagnostics GmbH